Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. Zhang YW, et al. Among authors: essenburg c. Cancer Res. 2010 Sep 1;70(17):6880-90. doi: 10.1158/0008-5472.CAN-10-0898. Epub 2010 Jul 19. Cancer Res. 2010. PMID: 20643778
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.
Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF. Xie Q, et al. Among authors: essenburg c. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):570-5. doi: 10.1073/pnas.1119059109. Epub 2011 Dec 27. Proc Natl Acad Sci U S A. 2012. PMID: 22203985 Free PMC article.
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy.
Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, Furge K, Vande Woude GF, Shinomiya N. Xie Q, et al. Among authors: essenburg c. Genes Cancer. 2013 Jul;4(7-8):247-60. doi: 10.1177/1947601913501075. Genes Cancer. 2013. PMID: 24167653 Free PMC article.
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF. Sameni M, et al. Clin Cancer Res. 2016 Feb 15;22(4):923-34. doi: 10.1158/1078-0432.CCR-15-0187. Epub 2015 Oct 2. Clin Cancer Res. 2016. PMID: 26432786 Free PMC article.
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors.
Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z, Koeman J, Boguslawski EA, Grit J, Dodd RD, Khachaturov V, Cardona DM, Chen M, Kirsch DG, Maina F, Dono R, Winn ME, Graveel CR, Steensma MR. Peacock JD, et al. Among authors: essenburg cj. Cancer Res. 2018 Jul 1;78(13):3672-3687. doi: 10.1158/0008-5472.CAN-17-3167. Epub 2018 May 2. Cancer Res. 2018. PMID: 29720369 Free PMC article.
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston T, Eagleson B, Kesterson RA, Bronson RT, Bowman MJ, Graveel CR, Steensma MR. Dischinger PS, et al. Among authors: essenburg cj. NPJ Breast Cancer. 2018 Aug 30;4:29. doi: 10.1038/s41523-018-0080-8. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30182054 Free PMC article.
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Engstrom LD, et al. Among authors: essenburg cj. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765324 Clinical Trial.
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR. Linklater ES, et al. Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065. Oncotarget. 2016. PMID: 27655711 Free PMC article.
17 results